In order to implement the requirements of “carrying out skills training around professional inspector team construction” of leading Party group of the CFDA, to promote the capacity of inspectorate, and improve the professional skills and comprehensive quality of the inspectors, the Tenth Experts’ Forum was successfully held at CFDI according to the work plan of CFDI Academic Committee on Nov. 17, 2017. Yang Wenying, the Director of Center for Endocrine and Metabolic Diseases of China-Japan Friendship Hospital, was invited in this expert forum, and give a lecture on “How to Conduct Clinical Research of Diabetes Drug " in this forum.

Director Yang now acts as Director of Center for Endocrine and Metabolic Diseases, Director of Teaching and Research Department of Internal Medicine, Chief Physician, Doctoral Student and Postdoctoral Adviser of China-Japan Friendship Hospital, she also held the position of Director and Honorary Director of Chinese Diabetes Society, Vice Chairman of Asian Association Diabetes, Consultant of Central Health Protection Committee, Chief Editor and Editorial Board Member of several magazines and so on. In addition, she was honored as Heroine and Woman Pace-setter as well as other honors nationwide, also won the first prize for Beijing’s Scientific and Technological Advance, the second prize for Scientific and Technological Advance of Chinese Medical Association and National Medical Health System Advanced Individual as well as other several awards. Apart from those, she has published more than 460 papers in domestic and foreign core journals in recent years.

During the forum, Director Yang gave a lecture on diabetes’ pathogenesis, relevant therapeutic drug, mechanism of action of different drugs as well as other basic aspects, meanwhile made explanations about major concern for inspecting data quality of clinical drug trials on-site in combination with the cases in relation to the inspection of diabetes drug clinical trials data. With the explanations of Director Yang, participants not only have a further understanding of treatment drugs of diabetes, but also a more clear grasp of risks generated from diabetes drug clinical trials inspection.

Over 210 people from the Department of CFDI, the Center for Drug Certification of Beijing Food and Drug Administration, and 19 provincial drug inspectorate from the whole country synchronously watching through video system participated in the training.